Description:

Size: 100ul

Catalog no.: bs-5958R-A555

Price: 380 EUR

Product details

Gene ID Number

4299

Modification Site

None

Tested applications

IF(IHC-P)

French translation

anticorps

Modification

Unmodified

Clonality

Polyclonal

Excitation emission

553nm/568nm

Concentration

1ug per 1ul

Target Antigen

AF 4 protein

Crossreactivity

Human, Mouse, Rat

Conjugated with

ALEXA FLUOR® 555

Recommended dilutions

IF(IHC-P)(1:50-200)

Clone

Polyclonal antibody

Purification

Purified by Protein A.

Conjugation

Alexa Fluor,ALEXA FLUOR 555

Category

Conjugated Primary Antibodies

Host Organism

Rabbit (Oryctolagus cuniculus)

Also known as

Anti-AF 4 protein PAb ALEXA FLUOR 555

Specificity

This is a highly specific antibody against AF 4 protein.

Long name

AF 4 protein Polyclonal Antibody, ALEXA FLUOR 555 Conjugated

Cross-reactive species details

Due to limited amount of testing and knowledge, not every possible cross-reactivity is known.

Source

This antibody was obtained by immunization of the host with KLH conjugated synthetic peptide derived from human AF 4 protein

Storage conditions

Store this antibody in aqueous buffered solution containing 1% BSA, 50% glycerol and 0.09% sodium azide. Keep refrigerated at 2 to 8 degrees Celcius for up to one year.

Properties

For facs or microscopy Alexa 1 conjugate.Very high photo stable ALEXA conjugate.If you buy Antibodies supplied by Bioss Primary Conjugated Antibodies. ALEXA FLUOR they should be stored frozen at - 24°C for long term storage and for short term at + 5°C.

Synonyms

AF 4; AF 4 protein; AF-4 protein; AF4/FMR2 family member 1; AFF 1; AFF1; AFF1_HUMAN; ALL1 fused gene from chromosome 4; ALL1-fused gene from chromosome 4 protein; FEL; MLLT2; MYELOID/LYMPHOID OR MIXED LINEAGE LEUKEMIA TRANSLOCATED TO 2; MLLT2; Protein AF-4; Protein FEL; Proto-oncogene AF4.

Background of the antigen

Proto-oncogene AF-4 (or FEL) is a product of a chromosomal aberration of the human gene AFF1, which is associated with acute leukemias. The fusion of AF-4 on chromosome band 4q21 with the mixed lineage leukemia (MLL or HRX) gene on 11q23 results in a MLL-AF-4 chimeric transcription factor in which AF-4 contributes transcriptional effector properties and requires cell-specific accessory factors. MLL is involved in several chromosomal translocations associated with acute myeloid and lymphoid leukemia. The MLL-AF-4 fusion protein is expressed in all normal hematopoietic cells. The expression of MLL-AF-4 influences the production of protein cyclin-dependent kinase inhibitor (CDKN1B), suggesting that inhibition of MLL-AF-4 expression may be a powerful and highly specific treatment of chemotherapy-resistant leukemia.